bullish
Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path
170 Views17 Jun 2024 08:45
Cooperation with Takeda saves Ascentage from survival problem, but self-building sales team remains a challenge. Investors eye anther deal with MNC. Short-term market value target is 50% that of HCM.
What is covered in the Full Insight:
- Ascentage Pharma's partnership with Takeda
- Consequence of the partnership for Ascentage's financial status
- Future prospects of Ascentage's product olverembatinib
- Investors' inquiry about additional pipeline candidates
- Concern over Ascentage's capacity to commercialize on its own
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Aug.18)- COVID Is Here, BIOSECURE Act Update, Livzon Deserves More Patience18 Aug 2024
- China Healthcare Weekly (Aug.4)- Taiji Group & China TCM, TCM Formula Granules VBP, Keymed's Trouble04 Aug 2024
- China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao28 Jul 2024
- Asia Cement China (743.HK) Privatization- There May Be "Surprises" Despite Disappointing Offer Price10 Jun 2024
- Hutchmed China Ltd (13.HK/HCM.US) - High Growth Is Expected from 2024 to 202612 Mar 2024
- Ascentage Pharma (6855.HK) - May Not Survive "This Winter"22 Nov 2022
x